Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Injectable in Situ Cross-Linking Hydrogels for Local Antifungal Therapy

Injectable in Situ Cross-Linking Hydrogels for Local Antifungal Therapy

Thumbnail Image
Download
Name

Fink_Injectable In Situ.pdf

Size

297.24 KB

Format

Adobe PDF

Checksum (MD5)

5a4382e9318aa3351207d1957238ce17

Author(s)
Kohane, Daniel S.
•
Hudson, Sarah
•
Fink, Gerald R
•
Langer, Robert S
Date Issued
November 2009
Journal
Biomaterials
Publisher
Elsevier
Citation
Hudson, Sarah P. et al. “Injectable in situ cross-linking hydrogels for local antifungal therapy.” Biomaterials 31.6 (2010): 1444-1452.
Version
Author's final manuscript
Abstract
Invasive fungal infections can be devastating, particularly in immunocompromised patients, and difficult to treat with systemic drugs. Furthermore, systemic administration of those medications can have severe side effects. We have developed an injectable local antifungal treatment for direct administration into existing or potential sites of fungal infection. Amphotericin B (AmB), a hydrophobic, potent, and broad-spectrum antifungal agent, was rendered water-soluble by conjugation to a dextran-aldehyde polymer. The dextran-aldehyde–AmB conjugate retained antifungal efficacy against Candida albicans. Mixing carboxymethylcellulose-hydrazide with dextran-aldehyde formed a gel that cross-linked in situ by formation of hydrazone bonds. The gel provided in vitro release of antifungal activity for 11 days, and contact with the gel killed Candida for three weeks. There was no apparent tissue toxicity in the murine peritoneum and the gel caused no adhesions. Gels produced by entrapment of a suspension of AmB in CMC–dextran without conjugation of drug to polymers did not release fungicidal activity, but did kill on contact. Injectable systems of these types, containing soluble or insoluble drug formulations, could be useful for treatment of local antifungal infections, with or without concurrent systemic therapy.
Subjects
Controlled drug release
Hydrogel
Cellulose
Dextran
Biocompatibility
MIT Department
Massachusetts Institute of Technology. Department of Biology
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Attribution-Noncommercial-Share Alike 3.0 Unported
http://creativecommons.org/licenses/by-nc-sa/3.0/
Persistent DSpace Link
http://hdl.handle.net/1721.1/57431
DOI of Published Version
https://doi.org/10.1016/j.biomaterials.2009.11.016
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.